Acute rejection

Acute rejection is a major point of uncertainty in the management of HCV-infected kidney transplant recipients. HCV infection has been associated with altered immune responses, graft injury, and poorer transplant outcomes, but the available studies do not establish a single direction or mechanism for its effect on rejection. The issue is clinically decisive because treatment intended to control HCV after transplantation can itself endanger the renal allograft.

Immune Effects and Conflicting Evidence

The biological case for fewer rejection episodes begins with evidence that HCV may induce a state of immune deficiency in kidney recipients. Reported changes include a reduction in naive T-helper lymphocytes and altered proliferative responses of T lymphocytes to mitogens. Such changes would be expected to weaken cellular immune responses and thereby reduce the incidence of Acute rejection. Some clinical groups have reported precisely that pattern; in one long-term series, the rejection rate among HCV-infected recipients was 14.5% over a 20-year follow-up period.

Other studies, however, found a similar or even higher incidence of rejection in anti-HCV-positive recipients. The apparent contradiction is partly explained by the clinical profile of the patients who acquire HCV before transplantation. Longer time on dialysis, previous transplants, and greater exposure to blood transfusions increase the likelihood of HCV infection, but these same features also identify recipients with heightened immunological risk. HCV positivity may therefore function less as an isolated cause than as a marker embedded in a broader history of sensitization and transplant complexity.

Antibody-Mediated and Subclinical Injury

The disagreement extends to the type of rejection involved. In a series of 354 anti-HCV-positive kidney transplant patients, a higher incidence of antibody-mediated rejection was initially observed. After adjustment for a panel reactive antibody level above 20%, however, HCV infection was no longer an independent risk factor. This finding weakens the argument that HCV alone drives antibody-mediated injury and instead points toward the importance of pre-existing immunological sensitization.

The timing of transplantation also altered the observed pattern. Among anti-HCV-positive patients, the incidence of rejection was higher in recipients transplanted from 1998 to 2002 than in those transplanted from 1990 to 1994: 25% compared with 20.6%, a difference reported as statistically significant. The later cohort contained more second-transplant recipients and highly sensitized patients, offering a plausible explanation for the increase without resolving whether HCV had an independent biological effect.

Protocol-biopsy findings add a less visible dimension. In a series of 435 kidney transplant patients who underwent protocol biopsies during the first six months, subclinical rejection, chronic allograft nephropathy, and HCV infection were each independent risk factors for graft loss. The observation suggests that clinically silent immune injury may contribute to the poorer death-censored graft survival reported in HCV-infected recipients, even when overt Acute rejection rates appear inconsistent between studies.

Interferon as a Trigger of Rejection

The relationship becomes more direct when HCV therapy is administered after transplantation. Early studies gave standard alpha interferon alone to small groups of kidney transplant recipients at doses of 3–10 million units three times weekly. Aminotransferase levels improved in only about half of patients, virological response during treatment occurred in roughly one quarter, and sustained virological response was very uncommon. Side effects caused many patients to withdraw.

The most consequential toxicity was acute renal failure, which was linked to episodes of Acute rejection and resulted in some graft losses. Later analysis showed that most of these rejection episodes were humoral rather than purely cellular. Thus, interferon did not merely fail to control HCV reliably; it introduced an immunological hazard into an organ whose survival depended on carefully maintained tolerance.

A meta-analysis of interferon-based therapy in renal transplant patients identified 12 clinical trials involving 102 unique patients, only one of them controlled. The estimated sustained virological response rate was 18.0%, while the dropout rate was 35.0%. Graft dysfunction was the most frequent adverse effect requiring treatment interruption, accounting for 28 cases, or 71.7% of the interruptions reported in the analysis. The authors concluded that alpha-interferon-based therapy had poor tolerance and safety after renal transplantation, and subsequent recommendations advised against alpha- or pegylated interferon alone in HCV-positive kidney transplant recipients.

Consequences for Transplant Strategy

Because post-transplant interferon can precipitate rejection, efforts to eradicate HCV are generally directed toward the period before kidney transplantation whenever possible. The same concern shapes the broader assessment of transplant candidacy: HCV-infected candidates require staging of liver disease, and those with established or decompensated cirrhosis may need consideration for simultaneous liver–kidney transplantation rather than kidney transplantation alone.

The risk is balanced against the continuing benefit of transplantation. Despite increased mortality and complications in HCV-infected recipients, kidney transplantation remains the preferred form of renal replacement therapy for an HCV-infected patient with end-stage renal disease when advanced liver injury is absent. Acute rejection therefore occupies a double position in the clinical narrative: it is an uncertain outcome associated with the recipient’s infection and immunological history, and it is a clearly documented danger intensified by interferon exposure after transplantation. The evidence supports caution and pretransplant planning, but not the claim that HCV uniformly protects against or uniformly causes rejection.